HC Wainwright Reaffirms Buy Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $12.00 target price on the stock.

Separately, Chardan Capital dropped their price objective on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Femasys Stock Up 5.6 %

NASDAQ FEMY opened at $1.32 on Tuesday. Femasys has a 52 week low of $0.86 and a 52 week high of $2.40. The firm has a market capitalization of $30.23 million, a price-to-earnings ratio of -1.63 and a beta of -2.81. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company has a fifty day moving average of $1.13 and a two-hundred day moving average of $1.12.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. On average, analysts predict that Femasys will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares in the last quarter. Aljian Capital Management LLC purchased a new position in shares of Femasys during the third quarter valued at $27,000. XTX Topco Ltd raised its holdings in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Femasys in the fourth quarter worth about $25,000. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.